Skip to content
Lower risk Drug recall · FDA · Published November 18, 2024

Endo recalls Clonazepam tablets due to labeling error

Endo USA recalls 0.125 mg Clonazepam orally disintegrating tablets with incorrect labeling. Some cartons show wrong strength but blister strips indicate correct dosage. No action needed as the error is not dangerous.

🇺🇸 FDA recall #D-0179-2025DrugEndo ›
Take action

Contact the company

Recalling firmEndo USA, Inc.1400 Atwater Dr · Malvern, PA 19355-8701
✎ GovInfoNow plain-language explainer

Endo USA recalled 0.125 mg Clonazepam orally disintegrating tablets due to a labeling error. The error means some cartons show the wrong strength, but the actual tablets inside are correct. This does not pose a safety risk to users. Read more at govinfonow.com/recall/32411-endo-recalls-clonazepam-tablets-due-to-labeling-error.

Source Summary by GovInfoNow · govinfonow.com/recall/32411-endo-recalls-clonazepam-tablets-due-to-labeling-error · Updated August 17, 2026 · FDA enforcement record: FDA #D-0179-2025

Cite this page

“Endo recalls Clonazepam tablets due to labeling error.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32411-endo-recalls-clonazepam-tablets-due-to-labeling-error. Based on FDA recall #D-0179-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0179-2025%22&limit=1).

The FDA announced on Nov. 18, 2024, that Endo USA, Inc. is recalling Clonazepam Orally Disintegrating Tablets due to labeling errors regarding declared strength. The agency classified the Class I recall as voluntary.

How to tell if you have it

  • Brand: Endo
  • Product: Clonazepam Orally Disintegrating Tablets, USP, 0.125 mg, C-IV, Rx Only
  • Quantity: 60 tablets per carton (10 blister cards)
  • NDC#: 49884-306-02 (carton), NDC #: 49884-306-52 (blisters)
  • Lot #: 550174101
  • Expiration: 01/31/2027
  • Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977
  • Distribution: Nationwide in the USA

The hazard

The FDA stated that some cartons were incorrectly labeled regarding the declared strength of the drug. The agency noted that the blister strips inside the product carton reflect the correct strength.

Context

GovInfoNow's records show Endo USA, Inc. has issued four other recalls since Dec. 20, 2024, including a March 13, 2026, recall for Buprenorphine Injection due to crystallization risk and October 10, 2025, and September 5, 2025, recalls for Everolimus Tablets due to impurity risks. Other recent recalls of similar products include Inventia Chlorthalidone Recall (Sept. 3, 2026), Slate Run Recalls Eptifibatide Injection Due to Labeling Error (Feb. 12, 2026), and Inventia Healthcare Chlorthalidone Tablets Recall (June 5, 2026).

How to tell if you have this one

Check for cartons labeled with NDC 49884-306-02 (60 tablets) or NDC 49884-306-52 (blisters). The product was distributed by PAR Pharmaceutical with lot number 550174101, expiring 01/31/2027.

  • Brand
    Endo
  • Category
    Drug
FDA recall event · 4 products

All 4 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Ongoing
  • Distribution
    Nationwide in the USA
Recall numberProduct, codes & lotsQuantityNDC
D-0178-2025Clonazepam Orally Disintegrating Tablet, USP, 2 mg, C-IV, Rx Only, 60 Tablets per carton, 10 blister cards containing 6 tablets each, Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-310-02 (carton), NDC#: 49884-310-52 (blisters).; Lot # 550176501, 550176601, Exp 02/28/2027.9,816 cartons49884-306-02, 49884-307-02, 49884-308-02, 49884-309-02, 49884-310-02, 49884-310-52
D-0179-2025Clonazepam Orally Disintegrating Tablets, USP, 0.125 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-306-02 (carton), NDC #: 49884-306-52 (blisters).; Lot #: 550174101, Exp. 01/31/2027.8,029 cartons49884-306-02, 49884-307-02, 49884-308-02, 49884-309-02, 49884-310-02, 49884-306-52
D-0180-2025Clonazepam Orally Disintegrating Tablets, USP, 0.25 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-307-02 (carton), NDC #: 49884-307-52 (blisters).; Lot #s: 550142801, 550142901, 550143001, 550143101, 550143201, 550143301, 550143401, 550147201, 550147401, Exp. 08/31/2026.72,973 cartons49884-306-02, 49884-307-02, 49884-308-02, 49884-309-02, 49884-310-02, 49884-307-52
D-0181-2025Clonazepam Orally Disintegrating Tablets, USP, 1 mg, C-IV, Rx Only, 60 tablets per carton (10 blister cards containing 6 tablets each), Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977, NDC#: 49884-309-02 (carton), NDC #: 49884-309-52 (blisters).; Lot #s: 550145201, Exp. 08/31/2026; 550175901, 550176001, 550176201, Exp. 02/28/202722,513 cartons49884-306-02, 49884-307-02, 49884-308-02, 49884-309-02, 49884-310-02, 49884-309-52
Based on the official FDA remedy

What to do — step by step

  1. Check Labeling

    Verify the blister strips inside the carton show the correct strength (0.125 mg) as the carton may have an incorrect label.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 58 days after the firm started it.

1. Firm started the recall: Nov 18, 202412. FDA classified it Class I: Jan 3, 202523. Published in FDA’s Enforcement Report: Jan 15, 2025320242025
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0179-2025 (November 18, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0179-2025 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA